| dc.contributor.author | Slyker, Jennifer A. | |
| dc.contributor.author | Corey, Casper | |
| dc.contributor.author | Kenneth, Tapia | |
| dc.contributor.author | Barbra, Richardson | |
| dc.contributor.author | Lisa, Bunts | |
| dc.contributor.author | Meei-Li, Huang | |
| dc.contributor.author | Dalton, Wamalwa | |
| dc.contributor.author | Sarah, Benki-Nugent | |
| dc.contributor.author | Grace, John-Stewart | |
| dc.date.accessioned | 2014-07-15T07:45:45Z | |
| dc.date.available | 2014-07-15T07:45:45Z | |
| dc.date.issued | 2014 | |
| dc.identifier.citation | Slyker, Jennifer A., et al. "Accelerated Suppression of Primary Epstein-Barr Virus Infection in HIV-Infected Infants Initiating Lopinavir/Ritonavir-Based Versus Nevirapine-Based Combination Antiretroviral Therapy." Clinical Infectious Diseases 58.9 (2014): 1333-1337. | en_US |
| dc.identifier.uri | http://cid.oxfordjournals.org/content/58/9/1333.full.pdf+html | |
| dc.identifier.uri | http://hdl.handle.net/11295/72990 | |
| dc.description.abstract | We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan human immunodeficiency virus–infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest that specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | University of Nairobi, | en_US |
| dc.title | Accelerated Suppression of Primary Epstein-Barr Virus Infection in HIV-Infected Infants Initiating Lopinavir/Ritonavir-Based Versus Nevirapine-Based Combination Antiretroviral Therapy | en_US |
| dc.type | Article | en_US |
| dc.type.material | en_US | en_US |
